World Health Organization site
Skip Navigation Links

Please fill this short user satisfaction survey


Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 8 January 2024
Main ID:  EUCTR2019-001866-14-HU
Date of registration: 02/08/2021
Prospective Registration: Yes
Primary sponsor: AstraZeneca AB
Public title: Open-label Extension Study of Brazikumab in Crohn’s Disease
Scientific title: An Open-label, Long-term Extension Study of Brazikumab in Participants With Moderately to Severely Active Crohn’s Disease (INTREPID OLE)
Date of first enrolment: 09/11/2021
Target sample size: 150
Recruitment status: Not Recruiting
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001866-14
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: no Randomised: no Open: yes Single blind: no Double blind: no Parallel group: no Cross over: no Other: yes Other trial design description: Extension study If controlled, specify comparator, Other Medicinial Product: no Placebo: no Other: no Number of treatment arms in the trial: 2  
Phase:  Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): yes Therapeutic use (Phase IV): no
Countries of recruitment
Austria Canada Czech Republic Czechia France Germany Hungary India
Israel Italy Korea, Republic of Poland Russian Federation Slovakia South Africa Spain
Taiwan Ukraine United Kingdom United States
Contacts
Name: Clinical Study Information Center   
Address:  N/A N/A N/A United States
Telephone:
Email: information.center@astrazeneca.com
Affiliation:  AstraZeneca
Name: Clinical Study Information Center   
Address:  N/A N/A N/A United States
Telephone:
Email: information.center@astrazeneca.com
Affiliation:  AstraZeneca
Key inclusion & exclusion criteria
Inclusion criteria:
1 Male or female participants with successful completion or early termination due to lack of efficacy from Study D5271C00001 (Legacy # 3150-301-008).

2 No known history of active TB or latent TB without completion of appropriate intervention.

3 Each participant must have had the ileocolonoscopic procedure at the final visit (Week 52, Week 12, or early termination after Week 12 of Study D5271C00001 (Legacy # 3150-301-008).

4 Female participants of childbearing potential must have a negative urine pregnancy test prior to administration of study intervention and must agree to use a highly effective method of birth control (confirmed by the investigator) from randomization throughout the study duration and for at least 18 weeks after last dose of study intervention.

5 Nonsterilized males who are sexually active with a female partner of childbearing potential must comply with the methods of contraception during treatment and until the end of relevant systemic exposure in the male participant, plus a further 18 weeks.

6 Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.

7 Written informed consent from the participant has been obtained prior to any study related procedures.

8 Demonstration of adequate compliance with the study procedures in Study D5271C00001 (Legacy #3150 301-008) in the opinion of the investigator and/or sponsor.

9 Willingness and ability to attend all study visits, comply with the study procedures, read and write in order to complete questionnaires, and be able to complete the study.

The complete list of eligibility criteria are outlined in the study protocol.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 115
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 35

Exclusion criteria:
1 Any participant with an unresolved AE from the Study D5271C00001 (Legacy #3150 301-008) that would limit the participant’s ability to participate in or complete this study.

2 Current diagnosis of ischemic colitis, colonic mucosal dysplasia, or primary sclerosing cholangitis.

3 Organ or cell-based transplantation (eg, islet cell transplantation or autologous stem cell transplantation) with the exception of corneal transplant.

4 Any other condition or finding that, in the investigator’s or sponsor’s opinion, would either confound proper interpretation of the study or expose a participant to unacceptable risk.

5 History of cancer except for basal cell and/or squamous cell carcinoma of the skin, and carcinoma in situ of the cervix within 12 months of screening.

6 Participant meets criteria for discontinuation of study intervention during prior the D5271C00001 (Legacy #3150 301-008) study (excluding lack of efficacy).

7 Chronic hepatitis B or C infection.

8 Known history of primary immunodeficiency, splenectomy, or any underlying condition that predisposes the subject to infection, including HIV infection.

9 Prolonged QTcF interval (QTc >450 msec or QTC >480 for participants with bundle branch block; determined by central ECG), or conditions leading to additional risk for QT prolongation (eg, congenital long-QT syndrome).

10 Participant requires additional immunosuppressive therapy (aside from permitted concomitant medication), biological treatment, or prohibited treatment.

11 Participant received a Bacille Calmette-Guérin vaccination within 12 months of Week 0 (Visit 1) or any other live vaccine < 4 weeks prior to Week 0 (Visit 1) or is planning to receive any such vaccine over the course of the study.

12 Participant received a prohibited medication during participation in the lead-in study or during screening for this study.

13 Participant is planning to receive an investigational drug (other than study intervention) or investigational device at any time during Study D5271C00002 (Legacy #3150-303-008) with the exception of “registry” or “cohort” trials.

14 Participants with a known hypersensitivity to brazikumab or any of the excipients of the product.

15 Protocol-defined abnormal laboratory results at screening.


The complete list of eligibility criteria are outlined in the study protocol.


Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Moderately to Severely Active Crohn’s Disease
MedDRA version: 20.0 Level: LLT Classification code 10011402 Term: Crohn's disease (colon) System Organ Class: 100000004856
Intervention(s)

Product Name: Brazikumab
Product Code: MEDI2070
Pharmaceutical Form: Solution for infusion
INN or Proposed INN: BRAZIKUMAB
CAS Number: 1610353-18-8
Other descriptive name: Anti-Interleukin-23 Immunoglobulin G2 (IgG2) Human Monoclonal Antibody; also referred to as MEDI2070
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 120-

Product Name: Brazikumab
Product Code: MEDI2070
Pharmaceutical Form: Solution for injection
INN or Proposed INN: BRAZIKUMAB
CAS Number: 1610353-18-8
Other descriptive name: Anti-Interleukin-23 Immunoglobulin G2 (IgG2) Human Monoclonal Antibody; also referred to as MED2070
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 120-

Primary Outcome(s)
Secondary Objective: Not applicable
Primary end point(s): a AE/SAE
b Clinical laboratory values
c Vital signs
d ECG
Main Objective: To assess the safety of long-term treatment with brazikumab in participants who previously completed Study D5271C00001 (Legacy #3150- 301-008) or discontinued from the study at or after Week 12 due to lack of efficacy.
Timepoint(s) of evaluation of this end point: a across the 52-week treatment period
b across the 52-week treatment period
c across the 52-week treatment period
d across the 52-week treatment period
Secondary Outcome(s)
Secondary end point(s): Not applicable
Timepoint(s) of evaluation of this end point: Not applicable
Secondary ID(s)
NCT03961815
#3150-303-008
D5271C00002
111773
2019-001866-14-GB
Source(s) of Monetary Support
AstraZeneca AB
Secondary Sponsor(s)
Ethics review
Status: Approved
Approval date: 02/11/2021
Contact:
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history Please fill this short user satisfaction survey